EUVIMEDEUVIMED entdecken
Open Access

Identifying mitigating strategies for endothelial cell dysfunction and hypertension in response to VEGF receptor inhibitors

Nicholas D Camarda iD, Qing Lu, Dawn M Meola, Joshua J Man, Zeyuan Song, Richard J Travers, Katherine E Lopez, Sarah N Powers, Malvina Papanastasiou, Katherine C DeRuff, James Mullahoo, Shawn B Egri und 10 weitere

Clinical Science · 2024

DOI: 10.1042/cs20240537 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Science, 2024. Verfasst von Nicholas D Camarda und 21 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA, U.S.A. Hauptthemen laut MEDLINE: Hypertension, Doxazosin, Endothelial Cells, Receptors, Vascular Endothelial Growth Factor. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, National Institutes of Health (NIH), NHGRI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vascular endothelial growth factor receptor inhibitors (VEGFRis) improve cancer survival but are associated with treatment-limiting hypertension, often attributed to endothelial cell (EC) dysfunction. Using phosphoproteomic profiling of VEGFRi-treated ECs, drugs were screened for mitigators of VEGFRi-induced EC dysfunction and validated in primary aortic ECs, mice, and canine cancer patients. VEGFRi treatment significantly raised systolic blood pressure (SBP) and increased markers of endothelial and renal dysfunction in mice and canine cancer patients. α-Adrenergic-antagonists were identified as drugs that most oppose the VEGFRi proteomic signature. Doxazosin, one such α-antagonist, prevented EC dysfunction in murine, canine, and human aortic ECs. In mice with sorafenib-induced-hypertension, doxazosin mitigated EC dysfunction but not hypertension or glomerular endotheliosis, while lisinopril mitigated hypertension and glomerular endotheliosis without impacting EC function. Hence, reversing EC dysfunction was insufficient to mitigate VEGFRi-induced-hypertension in this mouse model. Canine cancer patients with VEGFRi-induced-hypertension were randomized to doxazosin or lisinopril and both agents significantly decreased SBP. The canine clinical trial supports safety and efficacy of doxazosin and lisinopril as antihypertensives for VEGFRi-induced-hypertension and the potential of trials in canines with spontaneous cancer to accelerate translation. The overall findings demonstrate the utility of phosphoproteomics to identify EC-protective agents to mitigate cardio-oncology side effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertensionDoxazosinEndothelial CellsReceptors, Vascular Endothelial Growth FactorAnimalsDogsHumansProteomicsBlood PressureMiceMice, Inbred C57BLLisinoprilMaleNeoplasmsAntihypertensive AgentsProtein Kinase InhibitorsAdrenergic alpha-1 Receptor AntagonistsSorafenib

Stichwörter der Autor:innen

cardio-oncologyendothelial cellshypertensionproteomicsvascular endothelial growth factor receptor inhibitior

Substanzen

DoxazosinReceptors, Vascular Endothelial Growth FactorLisinoprilAntihypertensive AgentsProtein Kinase InhibitorsAdrenergic alpha-1 Receptor AntagonistsSorafenib

Autor:innen und Institutionen

  • Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA, U.S.A.
  • Genetics, Molecular, and Cellular Biology Program, Tufts Graduate School of Biomedical Sciences, Boston, MA, U.S.A.
  • Tufts Cummings School of Veterinary Medicine, North Grafton, MA, U.S.A.
  • Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, MA, U.S.A.
  • Division of Hematology Oncology, Department of Medicine, Tufts Medical Center, Boston, MA, U.S.A.
  • Broad Institute, Boston, MA, U.S.A.

ORCID-Profile: Nicholas D Camarda

Förderung

  • NIH HHS
  • National Institutes of Health (NIH)
  • NHGRI NIH HHS
  • NIGMS NIH HHS
  • NCI NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Camarda, N. D., Lu, Q., Meola, D. M., Man, J. J., Song, Z., Travers, R. J., Lopez, K. E., Powers, S. N., Papanastasiou, M., DeRuff, K. C., Mullahoo, J., Egri, S. B., Davison, D., Sebastiani, P., Eblen, S. T., Buchsbaum, R., Huggins, G. S., London, C. A., Jaffe, J. D., …, & Jaffe, I. Z. (2024). Identifying mitigating strategies for endothelial cell dysfunction and hypertension in response to VEGF receptor inhibitors. Clinical Science. https://doi.org/10.1042/cs20240537

Vancouver

Camarda ND, Lu Q, Meola DM, Man JJ, Song Z, Travers RJ, et al. Identifying mitigating strategies for endothelial cell dysfunction and hypertension in response to VEGF receptor inhibitors. Clinical Science. 2024. doi:10.1042/cs20240537

BibTeX
@article{Camarda2024,
  author = {Camarda, Nicholas D and Lu, Qing and Meola, Dawn M and Man, Joshua J and Song, Zeyuan and Travers, Richard J and Lopez, Katherine E and Powers, Sarah N and Papanastasiou, Malvina and DeRuff, Katherine C and Mullahoo, James and Egri, Shawn B and Davison, Desiree and Sebastiani, Paola and Eblen, Scott T and Buchsbaum, Rachel and Huggins, Gordon S and London, Cheryl A and Jaffe, Jacob D and Upshaw, Jenica N and Yang, Vicky K and Jaffe, Iris Z},
  title = {Identifying mitigating strategies for endothelial cell dysfunction and hypertension in response to VEGF receptor inhibitors},
  journal = {Clinical Science},
  year = {2024},
  doi = {10.1042/cs20240537}
}
Kostenlos starten →